<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
      <PMID Version="1">35307304</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>21</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2531-1387</ISSN>
          <JournalIssue CitedMedium="Internet">
            <PubDate>
              <Year>2022</Year>
              <Month>Mar</Month>
              <Day>04</Day>
            </PubDate>
          </JournalIssue>
          <Title>Hematology, transfusion and cell therapy</Title>
          <ISOAbbreviation>Hematol Transfus Cell Ther</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Impact of baseline fluorescent antinuclear antibody positivity on the clinical outcome of patients with primary autoimmune hemolytic anemia.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">S2531-1379(22)00033-5</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.htct.2022.01.013</ELocationID>
        <Abstract>
          <AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Autoimmune haemolytic anaemia (AIHA) is an autoimmune disorder that can present in primary or secondary forms. The literature looking at impact of baseline fluorescent antinuclear antibody (FANA) positivity on outcomes of AIHA patients is infrequent.</AbstractText>
          <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To study the impact of baseline FANA positivity in patients with primary AIHA.</AbstractText>
          <AbstractText Label="METHOD" NlmCategory="METHODS">A prospective cohort study involving 29 consecutive primary AIHA patients presenting to the Haematology department from 2013 to 2015 was analysed. After recording baseline investigations including fluorescent ANA, all patients were treated as per the standard therapeutic protocols. Clinical remission, disease free survival, relapse, mortality were compared between the FANA positive and FANA Negative AIHA groups.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Baseline FANA positivity was found in 17 patients (58.62%). Both the groups were comparable in terms of age, sex, Hemoglobin, LDH at presentation, number of lines of treatment needed and duration of follow up. Evan's syndrome was seen in six of FANA positive patients which was statistically significant (0 v/s 6, p = 0.023). FANA positive patients had significantly higher rates of relapse per patient month follow up (1.22 v/s 3.57, p = 0.023) and lower rates of complete response (83.33% v/s 35.29%, p = 0.0118) and relapse free survival at five years. Morbidity and mortality were numerically higher in FANA positive patients.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Baseline FANA positivity among AIHA patients was found to be associated with lower complete response rates and higher relapse rates with possible higher rates of morbidity. Presence of FANA will give us prognostic value and help us in deciding the treatment options.</AbstractText>
          <CopyrightInformation>Copyright © 2022 Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by Elsevier España, S.L.U. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Rangnekar</LastName>
            <ForeName>Aseem</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Assistant professor, Department of Microbiology, Gandhi Medical College, Bhopal, Madhya Pradesh, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shenoy M</LastName>
            <ForeName>Suchitra</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Professor and Head, Department of Microbiology, Kasturba Medical College, Mangalore, Manipal Academy of Higher Education, Manipal, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mahabala</LastName>
            <ForeName>Chakrapani</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Professor, Department of Medicine, Kasturba Medical College, Mangalore, Manipal Academy of Higher Education, Manipal, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Balanthimogru</LastName>
            <ForeName>Prashantha</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Associate Professor, Department of Medicine and Department of Adult Hematology, Kasturba Medical College, Mangalore, Manipal Academy of Higher Education, Manipal, India. Electronic address: prashantha.b@manipal.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>03</Month>
          <Day>04</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Brazil</Country>
        <MedlineTA>Hematol Transfus Cell Ther</MedlineTA>
        <NlmUniqueID>101725732</NlmUniqueID>
        <ISSNLinking>2531-1379</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Anemia</Keyword>
        <Keyword MajorTopicYN="N">Antinuclear antibody</Keyword>
        <Keyword MajorTopicYN="N">Autoimmune hemolytic anemia</Keyword>
        <Keyword MajorTopicYN="N">Evans syndrome</Keyword>
        <Keyword MajorTopicYN="N">SLE</Keyword>
      </KeywordList>
      <CoiStatement>Conflicts of interest None.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>8</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>4</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>28</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>21</Day>
          <Hour>5</Hour>
          <Minute>33</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>aheadofprint</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35307304</ArticleId>
        <ArticleId IdType="doi">10.1016/j.htct.2022.01.013</ArticleId>
        <ArticleId IdType="pii">S2531-1379(22)00033-5</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
